Bandingkan Harga & Kinerja Surya Citra Media Tbk. (SCMA) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Surya Citra Media Tbk. dan Organon Pharma Indonesia Tbk.: Surya Citra Media Tbk. diperdagangkan di Rp199 (kapitalisasi pasar 12,84 T, volume 24 jam 43,17 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Surya Citra Media Tbk. jauh lebih besar — sekitar 123× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| SCMA | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 12,84 T | 104,4 M |
Volume | 43,17 jt | — |
Lot | 431,67 rb | — |
Perputaran | 8,6 M | — |
Harga Rata-rata | 199,25 | — |
Nilai Transaksi | 8,6 M | — |
Harga Ekuilibrium Indikatif | 199 | — |
Volume Ekuilibrium Indikatif | 44,9 rb | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Surya Citra Media Tbk.
PT Surya Citra Media Tbk (the Company) formerly PT. Surya Citra Televisi, or popularly known as SCTV, started operations in Surabaya the capital of East Java in 1990 as a regional television station to server the province and the island of Bali. In 1993, pursuant to moving its headquarters to Jakarta, SCTV began broadcasting nationwide. In 29 Jan 1999 PT Cipta Aneka Selaras was established at jakarta and the company changed to PT Surya Citra Media at 31 Dec 2001. PT Elang Mahkota Teknologi Tbk is the ultimate parent company of the Company and Subsidiaries.
Selengkapnya di halaman SCMA →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
